Dr. Jordan Sloshower
Co-Director
Clinical Specialties
Integrative psychiatry, psychedelic therapy, psychodynamic and mindfulness-based therapy, depression, anxiety, trauma-related disorders, substance use disorders.
Services Offered
Ketamine-assisted therapy, psychedelic integration and harm reduction, individual and group psychotherapy, medication management, ecotherapy, music therapy, psychedelic research & policy consulting.
Jordan Sloshower, MD, MSc is a board-certified psychiatrist, researcher, and educator specializing in integrative approaches to mental health and psychedelic-assisted therapies. Dr Sloshower completed his medical and psychiatric training at Yale University, where he co-founded the Yale Psychedelic Science Group and served as an investigator and therapist in several clinical trials of psilocybin-assisted therapy for major depression. He is currently co-director of West Rock Wellness, PLLC in New Haven, CT and a clinical instructor in the Yale Department of Psychiatry.
Treatment Approach
Having trained at Yale, Dr Sloshower possesses a solid foundation in conventional psychiatric and psychotherapeutic approaches. However, he brings a unique perspective and skillset to his work resulting from prior training in anthropology and global health, and deep interests in ceremonial uses of psychedelic plants, Buddhist philosophy, and alternative approaches to wellness. This informs Dr Sloshower’s holistic way of creatively combining therapeutic approaches from different traditions and paradigms with the aims of achieving deep understandings of patients’ suffering and delivering safe, effective treatments.
Dr Sloshower has spent the past decade researching and studying the therapeutic applications of psychedelic medicines (e.g. psilocybin, ketamine, MDMA, and ayahuasca) and how these novel treatments can be integrated with psychotherapy and other healing modalities to promote holistic healing. As a psychotherapist, Dr Sloshower blends elements of psychodynamic, acceptance and commitment, mindfulness-based, somatic, and cognitive-behavioral therapies.
Background
Dr Sloshower was born and raised in Winnipeg, Canada and completed a master's degree in medical anthropology at the University of Edinburgh prior to entering medical school at Yale University. During his medical training, he pursued global health research and clinical opportunities in India, Nepal, Ecuador, Peru, and South Africa. He has traveled extensively in Central and South America and is conversant in Spanish. Outside the clinic, Dr Sloshower enjoys spending time in nature, playing guitar, listening to music, and being with his family and friends.
Talks and Lectures available online
-
"An Overview of my Research with Psilocybin-assisted Therapy for Depression." American Journal of Endocannabinoid Medicine, online, 8 September 2023.
-
“The Promise and Perils of Psychedelic Therapy.” The Tom Ficklin Show. WNHH. 17 March 2023.
-
“Psilocybin-Induced Neuroplasticity in the Treatment of Major Depressive Disorder: An Exploratory Placebo-controlled, Fixed-order Trial.” Yale Seminar in Psychedelic Medicine, online, 20 February 2023.
-
“The Role of Psychological Flexibility in Psilocybin-Assisted Therapy of Major Depression”. Grand Rounds, Department of Psychiatry at Baystate Health-UMass Chan Medical School, online, 19 April 2022.
-
“The Promise and Perils of Psychedelic Therapy: Historical and Contemporary Social Justice Perspectives.” RebPsych 2020: Decolonizing Mental Health, online panel, 19 November 2020.
-
“Integrating Plant Medicines and Psychiatry: Theory and Methods of a Model Clinic.” Psychedelic Science 2017 Conference, Oakland, CA, 2017
Selected Publications
-
Sloshower J., Skosnik PD, et al. (2023). Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal of Psychopharmacology.
-
Skosnik, PD., Sloshower, J et al. (2023). Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal of Psychopharmacology. 37: 687–697.
-
Labate, B., Ermakova, A. O., Sloshower, J., et al. (2023). The DEA report on ayahuasca risks: “Science” in service of prohibition?. Journal of Psychedelic Studies.
-
Raison, C. L. et al. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA. 330, 843–853.
-
Prueitt, W. L. & Sloshower, J. (2022). Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees. Academic Psychiatry 1–4. doi:10.1007/s40596-022-01662-9.
-
Strauss, D., Salle, S. de la, Sloshower, J. & Williams, M. T. (2022). Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal of Medical Ethics. 48:728–737.
-
Sloshower, J., Guss, J., et al. (2020). Psilocybin-Assisted Therapy of Major Depressive Disorder Using Acceptance and Commitment Therapy as a Therapeutic Frame. Journal of Contextual Behavioral Science. 15, 12-19.
-
Guss, J., Krause, R. & Sloshower, J. (2020, August 13). The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame). https://psyarxiv.com/u6v9y/
-
Sloshower, J. (2018). “Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic.” Plant Medicines, Healing and Psychedelic Science: Cultural Perspectives. Eds Labate, Beatriz and Cavnar, Clancy. Springer.
-
Sloshower, J. (2017). “Is Psychiatry Ready for the Psychedelic Healing Paradigm?” Chacruna online magazine. http://chacruna.net/is-psychiatry-ready-for-psychedelic-healing/